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Abbreviations 
 
miRNA: microRNA 
OSCC: oral squamous cell carcinoma 
EMT: epithelial mesenchymal transition 
qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction 
SOCS1: suppressor of cytokine signaling 1 
STAT3: signal transducer and activator of transcription 3 
SEER: the surveillance, epidemiology, and end results 
N-cadherin: neural cadherin 
FFPE: formalin-fixed, paraffin-embedded 
TNM: tumor-node-metastasis 
DMEM: Dulbecco’s modified eagle medium 
SNORD95: small nucleolar RNA, C/D box 95 
RNU6B: RNA, U6 small nuclear 2 
CT: comparative threshold 
E-cadherin: epithelial cadherin 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase  
NC: negative control 
UTR: untranslated region 
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Abstract 
Background: Abnormal miRNA expression was recently implicated in the metastasis of 
oral squamous cell carcinoma (OSCC) with poor prognosis. The initiation of the 
invasion-metastases cascade involves epithelial-mesenchymal transition (EMT). The 
aim of the present study was to clarify if misexpression of miRNA, particularly 
miR-155-5p, contributes to OSCC metastasis through EMT.  
Methods: Tumor samples were collected from 73 subjects with OSCC. The transcripts 
were analyzed by quantitative reverse-transcription polymerase chain reaction 
(qRT-PCR), and correlations between miR-155-5p levels and clinical characteristics 
were investigated. OSCC cell lines were analyzed by miRNA microarray and by 
transfection with miR-155-5p mimics or inhibitors, followed by proliferation and 
wound-healing migration assays. qRT-PCR analyses of EMT makers in cells 
transfected with miR-155-5p inhibitor were performed. 
Results: High miR-155-5p expression was observed in tissue samples from subjects 
with OSCC that had metastasized to cervical lymph nodes. HSC-3 cells also strongly 
expressed miR-155-5p. The epithelial marker E-cadherin was strongly expressed in 
HSC-3 cells transfected with miR-155-5p inhibitor. In addition, there was a tendency of 
elevated SOCS1 and decreased STAT3 expression in those cells.  
Conclusion: The results suggest that miR-155-5p causes OSCC to metastasize, and 
miR-155-5p inhibitor may function as an EMT suppressor. 
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Introduction 
Oral cancer accounts for 1-5% of all malignant tumors in humans (1, 2), and 
oral squamous cell carcinoma (OSCC) comprises approximately 91% of all oral cancers 
(1). Despite advances in OSCC diagnosis and management, the Surveillance, 
Epidemiology, and End Results (SEER) data for 2011 show that the 5-year overall 
survival rate of patients with oral cavity and pharyngeal cancer has not significantly 
improved in the past decade (61.8%, 2002; 62.7%, 2011)(2). Therefore, we needed 
more effective methods for the diagnoses and managing OSCC. Metastases strongly 
decrease the likelihood of a favorable outcome for cancer. (3, 4) 
MicroRNAs (miRNAs) are short non-coding RNAs consisting of 20-22 
nucleotides which function in RNA silencing and post-transcriptional regulation of gene 
expression. (5, 6) As miRNA is involved in the normal functioning of cells, the 
abnormal expression of miRNAs has been implicated in numerous disease states by 
suppressing the translation of the target gene's mRNA (7-13), and miRNA-based 
therapies are under investigation. (14-17) Many miRNAs have subsequently been found 
to have links with various types of cancer. (18) OSCC-specific miRNAs have been 
identified (19-21), including miR-155. (22) Although altered miR-155 expression in 
OSCC cells is known to alter OSCC cell behavior (23-25), its role in OSCC is not clear.  
miRNAs are initially transcribed from their own genes or introns as several 
hundred nucleotides long RNAs named a primary miRNAs (pri-miRNAs), which 
contain about 80 nucleotide RNA hairpin loop. (26, 27) A single pri-miRNA may 
contain from one to six hairpin loop structures. RNase III, known as Drosha, cleaves 
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RNA into about eleven nucleotides from the hairpin base to liberate these hairpins from 
pri-miRNAs. (28, 29) The resulting product is often named as a precursor-miRNA 
(pre-miRNA). Exportin-5, the neucleocytoplasmic shuttler, exports pre-miRNA hairpins 
out of the nucleus. (30) In the cytoplasm, the RNase III enzyme Dicer cleaves the 
pre-miRNA hairpin (31) by interacting with 5’ and 3’ ends of the hairpin (32) and cuts 
away the loop joining the 3’ and 5’ arms, yielding an about 22 nucleotides length 
miRNA duplex named a mature miRNA. (31) The mature miRNA is a part of an active 
RNA-induced silencing complex (RISC), where the miRNA and its mRNA target 
interact, containing Dicer and many associated proteins (33) including Members of the 
Argonaute (Ago) protein. Ago protein family is central in RISC function. Argonautes 
are need for miRNA-induced silencing and contain two conserved RNA binding 
domains. They bind the mature miRNA and orient it for interaction with a target mRNA. 
RISC with incorporated miRNA is referred as “miRISC.” Although each strand of the 
duplex may potentially act as a functional miRNA, only one strand selected on the basis 
of its thermodynamic instability and weaker base pairing relative to the other strand is 
incorporated into the miRISC. (34-36) The position of the stem-loop may also influence 
the strand choice. (37) The other strand, named the passenger strand, is normally 
degraded due to its low expression level in the steady state.  
One miRNA is complementary to a part of one or more mRNAs for the 
purpose of the function of miRNA in gene repression. miRNAs often have only partly 
the right complementary sequence of nucleotides in the 3’UTR to bond with the target 
mRNA. As a result, these mRNA molecules are silenced by one or more of cleavage of 
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the mRNA strand, leading to destabilization of the mRNA through shortening of its 
poly A tail, and less efficient translation of the mRNA into proteins by ribosomes. 
(38-40) But translational repression is accomplished through whether mRNA 
degradation, the translational inhibition or combination of both processes is still unclear. 
Partially complementary miRNAs recognize their targets. Although, 6-8 nucleotides of 
5’ end of the miRNA, named seed region, have to be perfectly complementary. (41-44) 
miRNAs that are partially complementary to a target can also increase deadenylation, 
causing mRNAs rapid degrading. (45)  
The human genome is considered to encode over 2000 miRNAs (46-49) and 
appear to target about 30-60% of all human genes. (41,50) Estimates of the average 
number of unique mRNAs that are targets for repression by a typical miRNA vary, 
depending on the method used to make the estimate, (51) but a given miRNA may have 
hundreds of different mRNA targets, and a given target might be regulated by multiple 
miRNAs. (52-56) Hence, miRNA research has revealed multiple roles of miRNAs in 
many other biological processes.  
miRNA expression can be quantified in a two-step polymerase chain reaction 
process of modified RT-PCR followed by quantitative PCR. miRNAs can also be 
hybridized to microarrays, slides or chips with probes to hundreds or thousands of 
miRNA targets, so that relative levels of miRNAs can be determined in different 
samples. (57)  
miRNA mimics and inhibitors are used as analysis tools of miRNA function. 
(58-60) miRNA mimics and inhibitors provide means to study the function of specific 
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miRNAs in a range of organisms, and to validate their role in regulating targeting genes. 
miRNA mimics are small, chemically modified double-stranded RNA molecules that 
are designed to mimic endogenous mature miRNAs, resulting in artificial 
down-regulation of target mRNA translation and accompanied, in some cases, by 
reduction in transcript levels. (61) Like natural miRNAs, these mimics have two mature 
strands, one of which is functional and used by the Ago protein to target mRNA. 
miRNA inhibitors are chemically modified, single-stranded oligonucleotides designed 
to specifically bind to and inhibit endogenous miRNAs, resulting in artificial 
up-regulation of target mRNA translation. (62) The function of miRNA inhibitor is 
application of the antisense method using antisense nucleic acid. The antisense method 
is a method to inhibit or downergulate the target RNA by using antisense RNA 
molecules. (63, 64) Thus, it is possible to identify miRNA function in cells by specific 
strong inhibition of the target miRNA. (65, 66) These short RNA molecules are 
expected to be used as treatment agents for such human diseases as cancer. 
Before cells in the primary tumor can metastasize, they must undergo 
invasion via epithelial-mesenchymal transition (EMT). EMT is a process by which 
epithelial cells in primary tumor change into mesenchymal cells; i.e., they lose cell 
polarity and cell-cell adhesion mediated by E-cadherin repression, and break free of 
neighboring cells, thereby acquiring the ability to metastasize via vascular invasion. 
When these circulating tumor cells exit the vessels to form micrometastases, they 
undergo mesenchymal-epithelial transition (MET) for outgrowth at the metastatic sites; 
e.g., in the cervical lymph nodes in case of OSCC. Thus, EMT, and its reverse process, 
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MET, form the initiation and completion of the invasion-metastasis cascade. (67, 68) 
EMT and MET bring not only phenotypic but also functional changes to the 
cells. Epithelial cells are closely connected to each other by tight, gap and adherens 
junctions, have apico-basal polarity, polarization of the actin cytoskeleton and are 
bound to the basal membrane with their basal surface. On the other hand, mesenchymal 
cells lack such polarization, have a spindle-shaped morphology and interact with each 
other only through focal points. (69) Epithelial cells express high levels of epithelial 
biomarkers, E-cadherin, whereas mesenchymal cells express those of mesenchymal 
biomarkers, including vimentin and neural cadherin (N-cadherin), the latter is also 
known as cadherin-2. (70) E-cadherin is commonly found in epithelial tissues and plays 
a crucial role in cell-cell adhesion, forming the above-mentioned junctions to bind cells 
within tissues together. Vimentin is a primary cytoskeletal component of 
mesenchyme-derived cells or cells undergoing EMT. N-cadherin is commonly found in 
cancer cells; it frees cancer cells to metastasize by causing the failure of cell-cell 
adhesion. (71) Therefore, loss of E-cadherin is considered to be an essential event in 
EMT. EMT inducing transcription factors (EMT-TFs) that can repress E-cadherin 
directly or indirectly are previously identified. Snail, Slug, Zeb1 and Zeb2 can repress 
E-cadherin directly by binding E-cadherin promoter and repress its transcription, 
whereas factors such as Twist repress E-cadherin indirectly. (72, 73) Since EMT occurs 
during cancer progression, many of the EMT-TFs are thought to be involved in 
development of metastases. On the other hand, a recent study also showed that some 
miRNAs contribute to EMT. (74-76) 
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Suppressor of cytokine signaling 1 (SOCS1) is recently identified as a novel 
miR-155 target in several cancer cells. (77, 78) SOCS1 is a protein that is encoded by 
the SOCS1 gene in humans (79, 80). It is a tumor suppressor that functions as a 
negative feedback regulator of Janus activated kinase (JAK)/signal transducer and 
activator of transcription (STAT) signaling. SOCS genes, also known as SOCS family,  
encode a member of the STAT-induced STAT inhibitor (SSI). SSI family members are 
cytokine-inducible negative regulators of cytokine signaling. The protein encoded by 
this gene functions downstream of cytokine receptors, and takes part in a negative 
feedback loop to attenuate cytokine signaling. Signal transducer and activator of 
transcription 3 (STAT3) is a transcription factor that is encoded by the STAT3 gene in 
humans. (81) Constitutive STAT3 activation is associated with various human cancers 
and commonly suggests poor prognosis. (82-85) The STAT protein regulates many 
aspects of growth, survival and differentiation in cells. The transcription factors of this 
family are activated by JAK. (86) In addition, STAT3 is described to modulate the 
expression of EMT transcriptional factors, including Twist, Snail, Zeb1, Zeb2, and Slug. 
(87, 88) 
In this study, I, with colleagues found that miR-155-5p was significantly 
upregulated both in OSCC cell lines and in formalin-fixed, paraffin-embedded (FFPE) 
tissue samples from patients with OSCC metastases to cervical lymph nodes, which is 
associated with a poor prognosis. I, with colleagues also found that HSC-3 cells 
expressed increased levels of E-cadherin and decreased levels of N-cadherin and 
vimentin mRNAs when transfected with an miR-155-5p inhibitor. Furthermore, there 
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was trend that SOCS1 was upregulated and STAT3 was downregulated in HSC-3 cells 
transfected with the miR-155-5p inhibitor.  
My results showed that miR-155-5p expression correlated significantly with 
metastasis to the cervical lymph nodes in OSCC and with a poor prognosis. My findings 
also suggest that miR-155-5p would be a potential novel target for the prevention of 
OSCC metastasis. 
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Materials and methods 
Clinical samples 
The study included 73 patients with OSCC and five patients who did not have cancer. 
All subjects visited the University of Tsukuba Hospital for the first time between 
February 2008 and November 2010, and tissue samples were collected on each subject's 
first visit, before administering treatment. Patients with oral cancers other than OSCC 
were excluded from this study. Samples of oral tumors were collected as part of a 
biopsy procedure. Thirty-four samples were from the tongue, 25 from the gingiva, seven 
from the cheek, four from the floor of the mouth, and three from the soft palate. Five 
patients without OSCC who had an impacted wisdom tooth volunteered to provide an 
oral biopsy sample for this study. All control samples were from the gingiva around the 
wisdom tooth. The samples were prepared for FFPE histology using standard 
procedures. OSCC was diagnosed and classified based on the Tumor-Node-Metastasis 
(TNM) system of Unio Internationalis Contra Cancrum. All cases were diagnosed 
histologically and clinically, as confirmed by pathologists. The median follow-up period 
was 24 months (range, 3–50 months).  
Table 1 shows the clinical characteristics of subjects with OSCC. Follow-up 
data were obtained from each patient's medical chart. Disease-free survival time was 
calculated from the date of the patient's first visit to a final time point of 60 months, 
when the overall survival rate was poor.   
This study was reviewed and approved by the Ethics Committee University of 
Tsukuba Hospital (No.215). All patients gave informed written consent prior to 
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enrollment. 
 
Cell lines, reagents, and cultures 
HaCaT and HSC-3 cell lines were obtained from the Japanese Collection of Research 
Bioresources. HSC-3 is a human oral squamous carcinoma cell line with high metastatic 
potential. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (Nichirei Bioscience, Tokyo, Japan) and 1% 
penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
HaCaT cells, an immortalized human keratinocyte line, were used as a control. 
 
TaqMan-based quantitative reverse-transcription polymerase chain reaction 
(qRT-PCR) assays of miRNA expression 
Mature miRNA expression levels were analyzed by TaqMan miRNA assay. 
Total RNA was extracted with the miRNeasy Mini Kit (Qiagen, Venlo, Limburg, 
Netherlands) for cell lines and the miRNeasy FFPE Kit (Qiagen). Total RNA was then 
reverse-transcribed into complementary DNA using a TaqMan MicroRNA 
Reverse-Transcription Kit (Applied Biosystems, Foster city, CA). The miR-155-5p 
level in the HSC-3 cell line was compared with the level in HaCaT cells. PCR reactions 
were first incubated at 16°C for 30 min and then at 42°C for 30 min, followed by 
inactivation at 85°C for 5 min. For the miRNA microarray analysis, reactions were then 
incubated in an miRNA PCR array platform (Human Cancer Pathway Finder miScript 
miRNA PCR array, MIHS-102Z, Qiagen), and other samples were incubated in a 
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384-well plate at 50°C for 2 min and at 95°C for 10 min, followed by 40 cycles of 95°C 
for 15 s and 60°C for 1 min, using the 7500 Fast Real-Time PCR System (Applied 
Biosystems) for MIHS-102Z, and the CFX384 Real-Time System (Bio-Rad 
Laboratories, Pleasanton, CA, USA) for 384-well plates. Relative miRNA expression 
was normalized against SNORD95 in the miRNA microarrays, and other samples were 
normalized against RNU-6B. Relative expression was calculated by the comparative 
threshold (CT) method. All experiments were performed at least in quintuplicate.  
 
TaqMan-based qRT-PCR assays of mRNA expression 
The qRT-PCR primers for E-cadherin, N-cadherin, and vimentin mRNA were as 
described previously (89-91): E-cadherin, 5’-TGCCCAGAAAATGAAAAAGG-3’ 
(forward) and 5’-GTGTATGTGGCAATGCGTTC-3’ (reverse); N-cadherin, 
5’-ACAGTGGCCACCTACAAAGG-3’ (forward) and 
5’-CCGAGATGGGGTTGATAATG-3’ (reverse); vimentin, 
5’-GAGTCCACTGAGTACCGGAGAC-3’ (forward) and 
5’-TGTAGGTGGCAATCTCAATGTC-3’ (reverse); SOCS1, 5′-GAGGGAGC 
GGATGGGTGTA-3′ (forward) and 5′-GAGGTAGGAGGT GCGAGTTCAG-3′ 
(reverse); and STAT3, 5′-CCAAGGAGGAGG CATTCG-3′ (forward) and 
5′-ACATCGGCAGGTCAATGG-3′ (reverse). Total RNA was extracted with the 
RNeasy Mini Kit (Qiagen) and then reverse-transcribed into complementary DNA using 
a PrimeScript RT Reagent Kit (TaKaRa, Shiga, Japan). PCR reactions were first 
incubated at 16°C for 30 min and then at 42°C for 30 min followed by inactivation at 
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85°C for 5 min. Reactions were then incubated in a 384-well plate at 95°C for 20 s, 
followed by 40 cycles of 95°C for 3 s and 60°C for 30 s using the CFX384 Real-Time 
system (Bio-Rad Laboratories). Relative mRNA expression was normalized against 
GAPDH. Relative expression was calculated by the CT method. All experiments were 
performed at least in quintuplicate. 
 
Transfection with miR-155-5p mimic or inhibitor  
Cells were transfected with miR-155-5p mimic or inhibitor or with scrambled negative 
control (NC; Ambion, Austin, TX, USA) using Lipofectamine RNAiMAX (Invitrogen, 
Carlsbad, CA, USA). Twenty-four hours after the beginning of the transfection, I, with 
colleagues isolated RNA and assayed cell proliferation and wound-healing migration. 
 
Cell-proliferation assay 
HSC-3 cells were seeded in triplicate 6-well plates with 3 ml of cell suspension per well 
(total 2.5 × 105 cells/well) and incubated for 24 h to allow attachment. The cells were 
transfected with miR-155-5p mimic or inhibitor or with NC, and were counted 24 and 
48 h after transfection using a TC10 (Bio-Rad) automated cell counter. 
 
Wound-healing migration assay 
HSC-3 cells were seeded in 6-well plates with 3 ml of cell suspension per well (total 2.5 
× 105 cells/well), cultured until approximately 80% confluent, and then transfected with 
miR-155-5p mimic or inhibitor or with NC. Twenty-four hours later, the cells were 
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washed twice with phosphate-buffered saline, starved by incubation in serum-free 
medium for 24 h, and then a wound was simulated with a straight scratch using a 200-µl 
pipette tip. The cells' migratory ability was measured by photographing the wound area 
every 3 h and quantifying it by ImageJ software (U. S. National Institutes of Health). 
(92, 93) All experiments were performed at least in duplicate. 
 
Statistical analysis 
Data from the OSCC cell line were compared by the Student’s t-test. Data from the 
FFPE tissue samples were compared by the Mann-Whitney U-test. Data from the 
Student’s t-test are presented as the mean + standard deviation, and data from the 
Mann-Whitney U-test are presented as boxplots. Data from cervical lymph-node 
metastasis and disease-free survival data were analyzed by the chi-square test. Survival 
data were analyzed by Kaplan-Meier survival analysis; Kaplan-Meier curves were 
compared using the log-rank test. In chi-square tests and the Kaplan-Meier survival 
analysis, the miR-155-5p expression level was classified as high or low by normalizing 
miR-155-5p expression to that of normal tissue (expression of miR-155-5p in normal 
tissue = 1, high > 1, low < 1). Data from FFPE tissue samples and patients’ clinical 
characteristics, including treatments for OSCC, were used for multivariate analysis of 
prognostic variables by Cox regression analysis. Metastasis to cervical lymph nodes 
was excluded from the multivariate analysis because of its obvious contribution to a 
poor prognosis. A two-tailed P value <0.05 was considered to be statistically significant. 
All statistical analyses were performed using JMP for Macintosh version 11 (SAS 
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institute).  
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Results 
High miR-155-5p expression was associated with poor overall survival in OSCC 
patients 
To determine the clinical significance of miR-155-5p expression, tissue samples from 
patients with OSCC and those without cancer were collected, prepared for FFPE, and 
analyzed by qRT-PCR. The miR-155-5p levels were then compared with patients’ 
clinical characteristics, to look for significant correlations (n=73; Table 1) after 
confirmation that there were no statistically significant differences in expression of 
miR-155-5p between each site. Mann-Whitney U and chi-square tests showed that high 
miR-155-5p expression was positively correlated with cervical lymph-node metastasis 
in OSCC patients (Fig. 1a, b). Kaplan-Meier survival analysis of miR-155-5p 
expression and OSCC recurrence or metastasis showed a significant correlation between 
high miR-155-5p expression and a poor disease-free survival rate (P = 0.017, Fig. 1c). 
In addition, multivariate analysis of prognostic variables in OSCC patients identified 
miR-155-5p expression as the specific factor leading to a poor OSCC prognosis (P = 
0.023, Table 2).  
 
miR-155-5p was upregulated in OSCC cells 
To determine which miRNAs are differentially expressed in HSC-3 cells, I, with 
colleagues analyzed 84 miRNAs by microarray, using the Human Pathway Finder 
miRNA PCR Array: MIHS-102Z (Fig. 2a-c). I, with colleagues found that miR-146a-5p, 
miR-10b, miR-155-5p, and miR10a-5p were upregulated more than 4-fold in HSC-3 
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cells. Conversely, 38 miRNAs were downregulated, albeit less than 4-fold (Fig. 2b). 
Furthermore, the expression of miR-155-5p was 8.04-fold higher in the HSC-3 cells 
than in the HaCaT cells (Fig. 2c). 
 
Effect of miR-155-5p mimic or inhibitor on OSCC-cell proliferation and migration 
I, with colleagues investigated correlations between miR-155-5p and the ability of 
HSC-3 cells to proliferate and migrate by assaying cell proliferation and wound-healing 
migration in cells transfected with an miR-155-5p mimic or inhibitor. I, with colleagues 
first confirmed that transfection was successful by performing qRT-PCR for 
miR-155-5p. Proliferation did not differ markedly between HSC-3 cells transfected with 
the miR-155-5p mimic or the inhibitor (Fig. 3a). Furthermore, although there was no 
statistically significant difference, the migratory ability of HSC-3 cells tended to 
increase by the miR-155-5p mimic and to decrease by the miR-155-5p inhibitor (Fig. 
3b). Together, my data suggest that miR-155-5p may affect the ability of HSC-3 cells to 
migrate rather than their ability to proliferate. 
 
Effect of miR-155-5p on E-cadherin, N-cadherin, and vimentin mRNA expression 
To investigate correlations between miR-155-5p and the mRNA of genes related to 
epithelial or mesenchymal properties, I, with colleagues analyzed E-cadherin, 
N-cadherin, and vimentin in HSC-3 cells transfected with miR-155-5p inhibitor. 
E-cadherin was significantly upregulated in HSC-3 cells transfected with the 
miR-155-5p inhibitor (Fig. 4a). In contrast, N-cadherin and vimentin tended to be 
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downregulated in HSC-3 cells transfected with the miR-155-5p inhibitor (Fig. 4a).  
 
miR-155-5p inhibitor suppressed the STAT3 signaling pathway through SOCS1 
To identify the biological mechanism by which miR-155-5p inhibitor mediates the 
upregulation of E-cadherin and the downregulation of N-cadherin and vimentin, I, with 
colleagues used qRT-PCR to analyze SOCS1 and STAT3 in HSC-3 cells transfected 
with miR-155-5p inhibitor. I, with colleagues found trends for SOCS1 to be upregulated 
and STAT3 to be downregulated (Fig. 4b).  
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Discussion 
The most fatal characteristics of oral squamous cell carcinoma is its potential 
for metastasis. When removing a primary OSCC tumor, surgeons may also remove 
nearby lymph tissue—especially cervical lymph nodes, as these are frequently the first 
metastasis sites. Once OSCC metastasizes to the lymph system, the likelihood of a 
favorable outcome decreases significantly. (3, 4) My study suggests that miR-155-5p 
induces metastasis to the lymph nodes, which leads to a poor prognosis. Thus, 
miR-155-5p might be a useful prognostic biomarker and an important therapeutic target 
for OSCC.  
High levels of miR-155-5p were significantly associated with a poor 
prognosis, metastasis to cervical lymph nodes, and poor overall survival. Multivariate 
analysis confirmed that this association of miR-155-5p with a poor prognosis for OSCC 
was not influenced by other prognostic variables such as treatment, pTNM stage, or age. 
Therefore, miR-155-5p merits consideration as a potential prognostic biomarker.      
Analysis by miRNA microarray confirmed that the miR-155-5p levels were 
high in OSCC cell lines compared with HaCaT cells. The roles of miR-155 upregulation 
and EMT in metastasis have been investigated in several cancers. (94, 95) I, with 
colleagues hypothesized that miR-155-5p also plays a crucial role in OSCC metastasis 
through EMT and could serve as a novel target for OSCC treatment. To investigate 
miR-155-5p's effect on OSCC cell proliferation, migration, and expression of 
EMT-related mRNAs, I, with colleagues conducted a series of loss- and 
gain-of-function assays with an miR-155-5p mimic or inhibitor. My data showed that 
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increased miR-155-5p function caused trends toward enhanced OSCC-cell migration 
rather than enhanced proliferation. 
Recently, miRNAs have been found in serum, plasma, saliva, and other body 
fluids. In addition, circulating extracellular vesicles, such as exosomes, containing 
miRNA are significantly associated with treatment resistance, metastatic properties, and 
a poor prognosis. (96-98) These findings suggest that the effect of miRNAs is not 
limited to the cancer cell itself, but that miRNAs can influence the behavior of both 
neighboring and distant cells. In other words, miRNAs exert not only autocrine effects, 
but also paracrine or endocrine effects. The miRNAs contained in exosomes influence 
the microenvironment of cells in the stroma of the neoplasm, including endothelial cells 
and fibroblasts, permitting them to begin migrating and invading other tissues (96). This 
mechanism may explain why the changes in the HSC-3 cells’ migration were not 
statistically significant, even though a clear relationship between metastasis and the 
expression of miR-155-5p was shown in clinical samples.   
In HSC-3 cells transfected with miR-155-5p inhibitor, the epithelial marker 
E-cadherin was upregulated while the mesenchymal markers N-cadherin and vimentin 
decreased. During EMT, epithelial makers are progressively lost as mesenchymal 
markers increase, and the cells develop a mesenchymal phenotype. (70) However, one 
fundamental function of miRNA is to silence mRNAs by cleaving their target mRNA 
strand or by decreasing the efficiency of its translation into protein. Thus, I, with 
colleagues hypothesized that miR-155-5p induced EMT by inhibiting an unknown 
biological mechanism. This would explain the high levels of epithelial-related mRNAs 
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in HSC-3 cells transfected with miR-155-5p inhibitor and the high miR-155-5p levels in 
both the HSC-3 cell line and the FFPE tissue samples. This would also support the 
potential for developing a novel OSCC therapeutic agent based on miR-155-5p 
function.  
A recent study reported a STAT3-mediated association between miR-155 and 
EMT that leads to invasion and metastases. (91) In head and neck squamous cell 
carcinoma, previous study reported SOCS1 regulates STAT3 activation in cell line and 
tissue samples (99) and STAT3 alternation correlates with poor prognosis (100, 101) 
and is considered to be a novel therapeutic target. (102)  
Expression of E-cadherin mRNA was upregulated in HSC-3 cells transfected 
with miR-155-5p inhibitor (Fig. 4a), and significant contribution of miR-155-5p 
inhibitor to EMT inhibition was confirmed. Abundant expression of SOCS1 and STAT3 
mRNAs was also confirmed in HSC-3 cells. The SOCS1 and STAT3 levels showed 
tendencies to be up- and down- regulated, respectively, by the transfection with 
miR-155-5p inhibitor, although the changes were not statistically significant (Fig. 5). 
miR-155-5p inhibitor may function as an EMT suppressor that increases SOCS1 
expression and suppresses STAT3 signaling as previously described (77, 87). Thus, it is 
strongly suggested that miR-155-5p inhibitor causes inhibition of EMT, which could be 
mediated by the SOCS1-STAT3 signaling cascade. Further studies are needed to clarify 
the mechanisms how miR-155-5p inhibitor leads to EMT inhibition. 
Since, high correlation of miRNA expression and carcinogenesis is observed, 
the development of nucleic acid medicine for variety of human diseases like cancer 
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have been carried out. Recently, reducing expression level of the oncomiR has attracted 
attention as one of the developing therapeutic agents of human diseases including 
cancer. (103-106) In addition, use of the disease signature miRNAs has been 
increasingly investigated in clinical trials in several countries. (107)   
Taken together, my findings indicate that the induction of metastasis and the 
poor prognosis associated with high miR-155-5p expression may be a direct result of 
EMT. Although my results indicate that miR-155-5p merits consideration as a 
prognostic biomarker and a treatment target, the details of the mechanism by which 
miR-155-5p exerts its effects remain obscure. Furthermore, I, with colleagues have 
evaluated the function of miRNA only at the miRNA and mRNA levels, and since the 
no significant differences for N-cadherin, Vimentin, STAT3 and SOCS1 mRNA, it is 
only speculations that miR155-5p contributes to EMT through STAT3 signaling 
pathway via SOCS1 in HSC-3 cell. Further studies of OSCC, specifically focusing on 
mRNA translation to protein, will be necessary to determine the mechanism underlying 
miR-155-5p’s association with poor prognosis in more detail. Additionally, Only 73 
OSCC specimens from five different sites were included to this study. Although there 
was no statistically significant difference in miR-155-5p expression between each 
biopsy site, some factors may affect my results depending on which site in the oral 
cavity the biopsy is taken. Larger number of patients and comparison of each biopsy site 
may improve the study quality. 
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Figures and tables  
Table 1 Clinical characteristics of patients with oral squamous cell carcinoma
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Figure 1 Association of high miR-155-p expression with oral squamous cell carcinoma 
(OSCC) metastasis to neck lymph nodes and poor prognosis for OSCC 
 
(a) High miR-155-5p levels are found in tissue samples from OSCC patients with 
metastasis to neck lymph nodes (*P = 0.045). (b) miR-155-5p levels in formalin-fixed, 
paraffin-embedded (FFPE) tissue samples from patients with OSCC correlate with 
metastasis to neck lymph nodes. Significance of correlation between miR-155-5p 
expression in FFPE tissue samples and the clinical index (presence or absence of 
metastasis) are determined by chi-square test (P = 0.040). (c) Kaplan-Meier survival 
analysis support the correlation between a poor disease-free survival rate for OSCC 
patients and high miR-155-5p expression (P = 0.017).  
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Table 2 Cox-regression multivariate analysis of prognostic variables in oral squamous 
cell carcinoma patients
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Figure 2 miR-155-5p expression in HSC-3 cells
 
miRNA microarray analysis of 84 miRNAs that are expressed differently in HSC-3 vs. 
HaCaT cells. (a) miR-155-5p express more strongly in HSC-3 cells than HaCaT cells 
(black arrow). Clustergram generated from miRNA microarray data of HaCaT and 
HSC-3 cells. Red: high expression; green: low expression; levels are continuously 
mapped on the color scale at the bottom of the figure. (b) miR-155-5p expression is 
8.04-fold higher in HSC-3 cells than HaCaT cells. Scatterplot generated from miRNA 
microarray data from HaCaT and HSC-3 cells. (c) miR-155-5p expression is 
significantly higher in HSC-3 cells than HaCaT cells (*P = 0.026 x10-4).    
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Figure 3 Effect of miR-155-5p regulation on the proliferation and migration of HSC-3 
cells
 
(a) Proliferation assay of HSC-3 cells transfected with an miR-155-5p mimic or 
inhibitor. There are no significant differences in HSC-3 cell proliferation in either 
condition. (b) Wound-healing migration assay of HSC-3 cells. HSC-3 cells’ migration 
is increased by transfection with an miR-155-5p mimic and decreased by transfection 
with an miR-155-5p inhibitor, but the difference is not statistically significant.  
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Figure 4 Effect of miR-155-5p inhibitor on the expression of epithelial-mesenchymal 
transition related mRNA
 
(a) E-cadherin expression is significantly increased in HSC-3 cells transfected with an 
miR-155-5p inhibitor (*P = 0.041). HSC-3 cells transfected with an miR-155-5p 
inhibitor shows trends toward decreased N-cadherin and vimentin expression. (b) 
Suppressor of cytokine signaling 1 expression tend to be upregulated in HSC-3 cells 
after transfection with the miR-155-5p inhibitor, while STAT3 expression tend to be 
downregulated. 
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Figure 5 Suppressor of cytokine signaling 1 (SOCS1) is a potential target of 
miR-155-5p. miR-155-5p is associated with epithelial-mesenchymal transition (EMT) 
through STAT3-signaling modulation via SOCS1
 
(a) The seed region of miR-155-5p shows good complementarity to the SOCS1 3’UTR. 
(b) miR-155-5p induces EMT by upregulating STAT3 via SOCS1 downregulation. 
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